Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 5454-year-old woman is evaluated in the oncology clinic prior to initiating adjuvant therapy for early-stage, HER2-positive breast cancer. Her planned regimen includes weekly paclitaxel concurrently with trastuzumab. She has a history of well-controlled essential hypertension. The physician discusses the potential adverse effects of her targeted therapy, specifically emphasizing the risk of cardiotoxicity, and outlines a comprehensive monitoring protocol. Arrange the following steps regarding the cardiac monitoring and treatment evaluation for this patient in the correct chronological and clinical sequence.

  1. 1Obtain a baseline echocardiogram to evaluate the left ventricular ejection fraction (LVEF) prior to initiation of therapy.
  2. 2Perform routine reassessment of LVEF every 33 months during the active course of treatment.
  3. 3Withhold therapy if routine monitoring reveals an asymptomatic absolute decrease in LVEF of 16%16\% or greater from baseline.
  4. 4Repeat the echocardiogram in 44 weeks to assess for recovery of ventricular function before deciding on resumption.

Cevap

The correct sequence begins with a baseline LVEF assessment, followed by monitoring every 33 months, withholding the drug if a significant drop (≥16%\geq 16\%) occurs, and then rechecking in 44 weeks to determine if therapy can be safely resumed.
The standard protocol for trastuzumab cardiac monitoring involves first establishing a baseline LVEF, as the drug can cause reversible heart failure. During treatment, monitoring is conducted every 33 months. If a patient experiences an asymptomatic absolute decrease in LVEF of 16%16\% or greater from baseline (or a 10−15%10-15\% decrease that drops the LVEF below institutional normal limits), the medication must be temporarily withheld. Because this cardiotoxicity is often reversible, the next step in treatment evaluation is to repeat the echocardiogram in 44 weeks to check for LVEF recovery, which dictates if the drug can be restarted.

Adım Adım Çözüm

1
Identify the primary adverse effect of the prescribed medication that requires monitoring.
Trastuzumab causes Type II cardiotoxicity, leading to asymptomatic decreases in left ventricular ejection fraction (LVEF) or clinical heart failure.
Recognizing the specific toxicity dictates the required monitoring modality, which in this case is echocardiography or a MUGA scan.
2
Determine the initial workup required before starting the drug.
A baseline echocardiogram must be obtained prior to initiation.
A baseline value is necessary to calculate subsequent drops in LVEF and ensure the patient has adequate cardiac function to withstand the therapy.
3
Determine the appropriate interval for ongoing surveillance.
LVEF should be reassessed every 33 months during therapy.
Frequent, regular monitoring allows for the detection of asymptomatic decline in cardiac function before overt heart failure develops.
4
Identify the threshold for treatment modification and the subsequent follow-up.
Therapy is withheld for a 16%16\% or greater absolute drop in LVEF, followed by a repeat assessment in 44 weeks.
This establishes whether the cardiotoxicity is reversible (as is typical with trastuzumab) and guides the decision to safely resume or permanently discontinue the medication.

Anahtar Kavram

Patients receiving trastuzumab require baseline and ongoing evaluation of left ventricular ejection fraction (LVEF) every 33 months. If LVEF declines significantly, therapy should be held and cardiac function re-evaluated in 44 weeks.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru